Fulgent Total Current Liabilities from 2010 to 2024

FLGT Stock  USD 20.56  0.20  0.98%   
Fulgent Genetics Total Current Liabilities yearly trend continues to be comparatively stable with very little volatility. Total Current Liabilities will likely drop to about 49.4 M in 2024. Total Current Liabilities is the total amount of liabilities that Fulgent Genetics is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations. View All Fundamentals
 
Total Current Liabilities  
First Reported
2015-12-31
Previous Quarter
61.4 M
Current Value
73 M
Quarterly Volatility
61.1 M
 
Yuan Drop
 
Covid
Check Fulgent Genetics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Fulgent main balance sheet or income statement drivers, such as Discontinued Operations of 49.5 K, Depreciation And Amortization of 33.3 M or Interest Expense of 38.9 M, as well as many exotic indicators such as Price To Sales Ratio of 2.83, Dividend Yield of 0.0015 or PTB Ratio of 0.72. Fulgent financial statements analysis is a perfect complement when working with Fulgent Genetics Valuation or Volatility modules.
  
This module can also supplement Fulgent Genetics' financial leverage analysis and stock options assessment as well as various Fulgent Genetics Technical models . Check out the analysis of Fulgent Genetics Correlation against competitors.
For more information on how to buy Fulgent Stock please use our How to Invest in Fulgent Genetics guide.

Latest Fulgent Genetics' Total Current Liabilities Growth Pattern

Below is the plot of the Total Current Liabilities of Fulgent Genetics over the last few years. Total Current Liabilities is an item on Fulgent Genetics balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Fulgent Genetics are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. It is the total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations. Fulgent Genetics' Total Current Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Fulgent Genetics' overall financial position and show how it may be relating to other accounts over time.
Total Current Liabilities10 Years Trend
Slightly volatile
   Total Current Liabilities   
       Timeline  

Fulgent Total Current Liabilities Regression Statistics

Arithmetic Mean33,374,975
Geometric Mean4,683,980
Coefficient Of Variation148.83
Mean Deviation42,089,833
Median2,925,000
Standard Deviation49,673,217
Sample Variance2467.4T
Range130.6M
R-Value0.71
Mean Square Error1317.2T
R-Squared0.50
Significance0
Slope7,887,573
Total Sum of Squares34544T

Fulgent Total Current Liabilities History

202449.4 M
202373 M
2022116.2 M
2021112.8 M
2020131.1 M
2019M
20182.7 M

About Fulgent Genetics Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Fulgent Genetics income statement, its balance sheet, and the statement of cash flows. Fulgent Genetics investors use historical funamental indicators, such as Fulgent Genetics's Total Current Liabilities, to determine how well the company is positioned to perform in the future. Although Fulgent Genetics investors may use each financial statement separately, they are all related. The changes in Fulgent Genetics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Fulgent Genetics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Fulgent Genetics Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Fulgent Genetics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Total Current Liabilities73 M49.4 M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Fulgent Genetics is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Fulgent Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Fulgent Genetics Stock. Highlighted below are key reports to facilitate an investment decision about Fulgent Genetics Stock:
Check out the analysis of Fulgent Genetics Correlation against competitors.
For more information on how to buy Fulgent Stock please use our How to Invest in Fulgent Genetics guide.
Note that the Fulgent Genetics information on this page should be used as a complementary analysis to other Fulgent Genetics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.

Complementary Tools for Fulgent Stock analysis

When running Fulgent Genetics' price analysis, check to measure Fulgent Genetics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Fulgent Genetics is operating at the current time. Most of Fulgent Genetics' value examination focuses on studying past and present price action to predict the probability of Fulgent Genetics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Fulgent Genetics' price. Additionally, you may evaluate how the addition of Fulgent Genetics to your portfolios can decrease your overall portfolio volatility.
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Commodity Directory
Find actively traded commodities issued by global exchanges
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Is Fulgent Genetics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Fulgent Genetics. If investors know Fulgent will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Fulgent Genetics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.99)
Earnings Share
(5.63)
Revenue Per Share
9.71
Quarterly Revenue Growth
0.041
Return On Assets
(0.03)
The market value of Fulgent Genetics is measured differently than its book value, which is the value of Fulgent that is recorded on the company's balance sheet. Investors also form their own opinion of Fulgent Genetics' value that differs from its market value or its book value, called intrinsic value, which is Fulgent Genetics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Fulgent Genetics' market value can be influenced by many factors that don't directly affect Fulgent Genetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Fulgent Genetics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Fulgent Genetics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Fulgent Genetics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.